NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $27.15 -1.11 (-3.93%) Closing price 11/16/2026 04:00 PM EasternExtended Trading$26.65 -0.50 (-1.84%) As of 05:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARQT alerts:Sign Up Key Stats Today's Range$27.03▼$28.4050-Day Range$23.38▼$34.0552-Week Range$19.30▼$34.80Volume1.70 million shsAverage Volume2.65 million shsMarket Capitalization$3.43 billionP/E Ratio129.29Dividend YieldN/APrice Target$39.75Consensus RatingModerate Buy Company Overview Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California. Arcutis primarily serves the U.S. market and continues to develop medicines for dermatologic conditions. Its leadership is headed by President and Chief Executive Officer Frank Watanabe.AI Generated. May Contain Errors. Read More Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreARQT MarketRank™: 4.305926321405 of 5 starsArcutis Biotherapeutics scored higher than 86% of companies evaluated by MarketBeat, and ranked 89th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialArcutis Biotherapeutics has a consensus price target of $39.75, representing about 46.4% upside from its current price of $27.15.Amount of Analyst CoverageArcutis Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth203.57% Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow by 203.57% in the coming year, from $0.28 to $0.85 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is 131.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is 131.10, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.38.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 14.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted15.85% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 7.58.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 11.37%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.59 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Arcutis Biotherapeutics this week, compared to 7 articles on an average week.Search Interest5 people have searched for ARQT on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows3 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,158,225.00 in company stock.Percentage Held by Insiders9.40% of the stock of Arcutis Biotherapeutics is held by insiders.Percentage Held by InstitutionsArcutis Biotherapeutics has minimal institutional ownership at this time.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARQT Stock News HeadlinesArcutis Biotherapeutics, Inc. Presents Caregiver-Reported Outcomes Data Supporting Zoryve Cream 0.05% for Mild to Moderate Atopic Dermatitis in InfantsNovember 14 at 7:31 AM | marketscreener.comMArcutis Biotherapeutics (ARQT) Stock Looks Expensive Despite Its Huge Three Year RunNovember 14 at 7:31 AM | finance.yahoo.comYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.November 17 at 1:00 AM | Profits Run (Ad)Arcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ...November 13, 2026 | markets.businessinsider.comArcutis Presents New Caregiver-Reported Outcomes Data Supporting ZORYVE® (roflumilast) Cream 0.05% for Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months at the ACAAI Annual Scientific MeetingNovember 13, 2026 | globenewswire.comArcutis Biotherapeutics, Inc. 2026 Q3 - Results - Earnings Call PresentationNovember 9, 2026 | seekingalpha.comArcutis Biotherapeutics (NASDAQ:ARQT) EVP Patrick Burnett Sells 943 Shares of Company StockNovember 5, 2026 | insidertrades.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock: Insider Howard Welgus Sells 4,728 SharesOctober 20, 2026 | insidertrades.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $29.04 at the beginning of the year. Since then, ARQT stock has decreased by 6.5% and is now trading at $27.15. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its quarterly earnings results on Wednesday, November, 4th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.18 by $0.12. The company earned $143.92 million during the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a net margin of 5.88% and a trailing twelve-month return on equity of 14.18%. Read the conference call transcript. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $150 million in an initial public offering on Friday, January 31st 2020. The company issued 9,375,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Top institutional shareholders of Arcutis Biotherapeutics include State Street Corp (6.10%), Goldman Sachs Group Inc. (1.30%), GW&K Investment Management LLC (1.07%) and Aberdeen Group plc (0.96%). Insiders that own company stock include Todd Franklin Watanabe, Todd Watanabe, Larry Todd Edwards, David Joseph Topper, Patrick Burnett, Masaru Matsuda, Latha Vairavan, Howard G Welgus, Sue-Jean Lin, Patrick J Heron, Terrie Curran, Neha Krishnamohan and Halley E Gilbert. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Micron Technology (MU), CrowdStrike (CRWD), Applied Digital (APLD) and Tesla (TSLA). Company Calendar Last Earnings11/04/2026Today11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (27m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ARQT's financial health is in the Green zone, according to TradeSmith. ARQT has been in this zone for over 27 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARQT CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees354Year Founded2016Price Target and Rating Average Price Target for Arcutis Biotherapeutics$39.75 High Price Target$48.00 Low Price Target$34.00 Potential Upside/Downside+46.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$0.21 Trailing P/E Ratio129.29 Forward P/E Ratio31.94 P/E GrowthN/ANet Income-$16.14 million Net Margins5.88% Pretax Margin6.06% Return on Equity14.18% Return on Assets6.28% Debt Debt-to-Equity Ratio0.42 Current Ratio2.92 Quick Ratio2.66 Sales & Book Value Annual Sales$376.07 million Price / Sales9.13 Cash FlowN/A Price / Cash FlowN/A Book Value$1.93 per share Price / Book14.07Miscellaneous Outstanding Shares126,460,000Free Float114,568,000Market Cap$3.43 billion OptionableOptionable Beta1.66 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ARQT) was last updated on 11/16/2026 by MarketBeat.com Staff. From Our PartnersPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredElon Musk… A Total Fraud?Jeff Brown, the former tech executive who picked Nvidia in 2016 before it surged as high as 37,800 percent, ju...Brownstone Research | SponsoredTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredNasdaq Biotech Clears FDA Milestone, Brings In Thermo FisherA NASDAQ-listed biotech just received FDA clearance to move its lead multiple sclerosis therapy, Lucid-MS, int...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.